Renal safety of tenofovir in HIV treatment-experienced patients.
about
In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cellsNucleoside/nucleotide analogues in the treatment of chronic hepatitis BA Single-Nucleotide Polymorphism in ABCC4 Is Associated with Tenofovir-Related Beta2-Microglobulinuria in Thai Patients with HIV-1 InfectionRisk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral TreatmentLong-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study.Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs.COHORT PROFILE: The Complications of Long-Term Antiretroviral Therapy study in Uganda (CoLTART), a prospective clinical cohort.Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transportersPopulation pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.Total protein, albumin and low-molecular-weight protein excretion in HIV-positive patients.Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B.Acyclic nucleoside phosphonates: a key class of antiviral drugs.Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimensImpact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study.Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunctionNephrotoxicity of HAARTRenal Function Recovery and HIV Viral Suppression Following Tenofovir Discontinuation for Renal Impairment.Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics.Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort.Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection.Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone.Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?Tenofovir-induced kidney injury.Antiretroviral-treated HIV-infected women have similar long-term kidney function trajectories as HIV-uninfected women.Estimated Glomerular Filtration Rate Increases in Chronic Hepatitis B Patients Treated With Telbivudine Monotherapy and Combination Treatment."One pill, once daily": what clinicians need to know about Atriplatrade mark.Tubulointerstitial nephropathies in HIV-infected patients over the past 15 years: a clinico-pathological study.Experience with tenofovir disoproxil fumarate for antiretroviral therapy.Renal function with use of a tenofovir-containing initial antiretroviral regimenThe effect of Tenofovir on renal function among Ugandan adults on long-term antiretroviral therapy: a cross-sectional enrolment analysis.Microalbuminuria in HIV disease.Incidence of stage 3 chronic kidney disease and progression on tenofovir-based regimensChanges in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis.Management of HIV and hepatitis virus coinfection.Safety evaluation of telbivudine.HIV therapies and the kidney: some good, some not so good?Update on tenofovir toxicity in the kidney.Emtricitabine/tenofovir in the treatment of HIV infection: current PK/PD evaluation.Hypophosphatemic osteomalacia induced by tenofovir in HIV-infected patients.Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention.
P2860
Q24674939-8EC400E7-52BB-4FF1-9D65-0B344F7B1B17Q27030828-FAFF97D9-93D1-4460-B6BB-6E24A1F239EAQ28552839-F3012C5E-E008-4EC7-BDD3-85EBC9994E50Q28554081-E6E5211E-93E0-40DD-B602-ED00F47148ABQ30983924-342384DE-34C4-4CE0-8D1E-55EF62572B2EQ33633267-0911AE36-D73E-4E0C-8FA5-268680C6E30DQ33640397-6585C118-1812-4AA2-80FB-8AA0FB22F021Q33845879-0C6ECA39-8DCC-4B9C-B68D-4CF6F8B1EE31Q33938112-C7FFABA7-E5CD-4293-B0AC-58225EA01604Q34375843-1B66CA83-6EC3-4EFD-BD8E-0F85A6FA7B52Q34409132-472563EB-A804-4EEE-9C35-FBD19AF66512Q34464655-FB6A0E68-C713-4ED3-824B-F846EFC7C441Q34488494-E49F2D2E-A6B1-4B5F-9E50-C94FEB97239EQ34787977-4D348397-CDF4-4FF7-8DA3-E4A70D0084E5Q35016654-02697131-32AE-4C6E-A1EA-6B8A1AA381DFQ35167944-0C59DF10-FD03-4593-B938-CF00109A6375Q35748339-2A3F7FA8-49C5-445D-AA1E-56F71BAA9632Q36081993-22611AE5-419A-4C76-906B-AE2D22765286Q36237157-E08A1359-79D2-4933-B2C8-525A810C761DQ36407276-6DBEC333-DAB5-47CE-87E3-2358F40BD653Q36607380-9B6924CD-CEB9-41F0-8BA7-4ED6C414149EQ36723853-6893FC5A-8FDA-4055-B6EB-976EAB8EF982Q36762441-B47F7226-E657-4B72-96F9-3538C1F92040Q36795839-F124BCEB-AA0D-4065-BF52-31CE715009DAQ36805345-B35A7BBB-9D43-4EE0-AF2A-C5A69FB45C31Q36823570-FF0CF6DD-52CD-46D5-9BB3-5EEAFAFEE557Q36910943-9E1F7D5C-1395-4535-AE97-7640DFA9EB5EQ37142078-565EA63B-3DBC-4778-8AE7-54E8E0EF503EQ37215065-1B250194-837E-4204-86B2-C717E55C10ACQ37221374-18322E60-45DD-443E-A88D-9E437801FFA5Q37259613-7D84011E-892D-4CB3-B620-B8DC64F488F1Q37263602-09DBDD53-A562-4233-B0B1-4677546D9E2CQ37665912-61DEC9AA-3A9B-4E0A-892F-474E237A6A7DQ37772508-8E86FFD8-AC21-4B06-8D0C-D59584C1FFE7Q37775959-A159C16C-C4AF-450F-8BC5-CEDB6863F7A7Q37988776-026CF43C-88CE-4FB6-8869-33C51FDA281BQ38033446-F25C2299-036A-4A29-AE2A-2AA36A49E48CQ38040137-3123ACC1-8AAA-4A9A-A0E4-18E6DEA205C1Q38209222-58E4CFE1-E03E-4197-A532-F048979BFC89Q38222708-6BB1F27A-69E0-4A75-8C06-A786A93F7FFB
P2860
Renal safety of tenofovir in HIV treatment-experienced patients.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Renal safety of tenofovir in HIV treatment-experienced patients.
@en
Renal safety of tenofovir in HIV treatment-experienced patients.
@nl
type
label
Renal safety of tenofovir in HIV treatment-experienced patients.
@en
Renal safety of tenofovir in HIV treatment-experienced patients.
@nl
prefLabel
Renal safety of tenofovir in HIV treatment-experienced patients.
@en
Renal safety of tenofovir in HIV treatment-experienced patients.
@nl
P2093
P50
P1433
P1476
Renal safety of tenofovir in HIV treatment-experienced patients
@en
P2093
Andrew Cheng
Carmen Kreft Jais
Daniel Vittecoq
Gilbert Deray
Hassane Izzedine
P304
P356
10.1097/00002030-200404300-00019
P407
P577
2004-04-01T00:00:00Z